The Institute of Pharmaceutical Innovation

Thursday 3rd July, 2008 Syntopix sign deal with Proctor and Gamble

Syntopix Group plc (AIM: SYN) the speciality pharmaceutical research and development company focused on dermatological diseases, is pleased to announce that it has entered into a joint development agreement with Procter & Gamble, the world’s largest consumer goods product company.

Under the terms of the agreement, Syntopix and Procter & Gamble will investigate the use of Syntopix’ novel antimicrobial technology with the objective of improving the efficacy of one of Procter & Gamble’s major consumer healthcare brands.

Financial details of the agreement are confidential though Procter & Gamble will have the opportunity to commercialise the Syntopix technology developed under the joint development agreement.

This latest agreement emphasises the Syntopix’ strategy of leveraging its compound library and intellectual assets into markets outside of dermatological disease and into broader consumer healthcare markets. This agreement follows an agreement announced in December 2007 with another major consumer healthcare company.

Dr Stephen Jones, Syntopix’ Chief Executive Officer, commented: “I am delighted that Syntopix has entered into this joint development agreement with Procter & Gamble, the world’s largest consumer goods product company. We believe that Syntopix’ antimicrobial technology has the potential to improve the effectiveness of consumer healthcare brands and it is particularly pleasing to sign this agreement with a company such as Procter & Gamble.

“This agreement validates our strategy of broadening the number of potential markets available to the antimicrobial expertise of Syntopix to include consumer healthcare, as well as the over the counter and prescription markets associated with treating dermatological conditions.”